QuidelOrtho (QDEL) – Company Press Releases
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, and Sharecare and Encourages Investors to Contact the Firm
-
QUIDELORTHO CORPORATION (NASDAQ: QDEL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds QuidelOrtho Corporation Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – QDEL
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho
-
QuidelOrtho To Report First Quarter 2024 Financial Results
-
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against QuidelOrtho Corporation (QDEL)
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – QDEL
-
QUIDELORTHO CORPORATION (NASDAQ: QDEL) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against QuidelOrtho Corporation
-
QUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against QuidelOrtho Corporation and Encourages Investors to Contact the Firm
-
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives
-
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Company and Certain Executives
-
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
-
ROSEN, A LEADING LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
QUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of QuidelOrtho Stockholders and Encourages Investors to Contact the Firm
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
QDEL ALERT: ROSEN, A RESPECTED AND LEADING FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
-
QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference
-
QuidelOrtho Announces Changes in Executive Leadership
-
Berman Tabacco Announces Investigation of QuidelOrtho Corporation (QDEL) for Potential Securities Law Violations
-
QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results
-
QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results
-
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
-
QuidelOrtho to Participate in the Evercore ISI Conference
-
QuidelOrtho Reports Third Quarter 2023 Financial Results
-
Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square
-
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
-
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
-
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
QuidelOrtho Reports Second Quarter 2023 Financial Results
-
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
-
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings
-
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings
-
QuidelOrtho to Report Second Quarter 2023 Financial Results
-
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
-
QuidelOrtho Reports First Quarter 2023 Financial Results
-
QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023
-
QuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)
-
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
-
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
-
ImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for Pharmacies
-
QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results
-
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
Back to QDEL Stock Lookup
